Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Study ID
- NCT02764268
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Apatinib — DRUG
Study Details
Apatinib dose titration in Advanced or Metastatic Gastric Cancer
Key Dates
- Start date
- Nov 2, 2016
- Status verified
- Apr 2016
- Primary completion
- Dec 10, 2018
- Completion
- Apr 15, 2019
Study Design
- Enrollment
- 60 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Apatinib
Primary Outcome Measure
Number of Participants With Dose Interruptions [ Time Frame: 15 months ]
Related Studies
- Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer PatientsRecruiting · Vanderbilt University Medical Center · Nashville, Tennessee
- The Gastric Cancer Foundation: A Gastric Cancer RegistryRecruiting · Stanford University · Stanford, California
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Feasibility of the LUM Imaging System for Detection of Gastrointestinal CancersPHASE1/PHASE2 · Recruiting · Lumicell, Inc. · Boston, Massachusetts